Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-01

Clinical Trial Update: LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial (LUME-Lung 1) evaluating BIBF 1120 (nintedanib) plus docetaxel vs placebo plus docetaxel in second-line non-small cell lung cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIBF 1120 (nintedanib)
  • DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2014-12-01